Black Friday Get Elite for just $149.00 Claim Now

Biohaven Reports Early Tumour Responses in Phase 1 Trial of Cancer Drug BHV-1530

By Fiona Craig | November 19, 2026, 8:43 AM

Biohaven Ltd. (NYSE:BHVN) reported encouraging preliminary clinical results from a Phase 1 study of its investigational antibody-drug conjugate BHV-1530, with tumour reductions and partial responses observed among patients with cancers carrying activating FGFR3 alterations.

The findings were presented on November 19, 2026, during an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

According to the company, nine of 10 efficacy-evaluable patients with activating FGFR3 alterations who received BHV-1530 at doses of at least 3.3 mg/kg experienced tumour reduction, while six achieved a partial response.

The investigational treatment also demonstrated a favourable preliminary tolerability profile, with no dose-limiting toxicities, treatment-related serious adverse events or treatment-related deaths reported among the 30 patients treated as of the October 19, 2026 data cutoff.

Biohaven plans to advance BHV-1530 into a pivotal clinical study targeting FGFR3-altered cancers, potentially beginning in the first half of 2027.

Phase 1 Study Shows Tumour Reduction in Nine of 10 Evaluable Patients

The Phase 1 trial is evaluating BHV-1530 as a monotherapy in patients with cancer, with dose escalation continuing.

As of the October 19 data cutoff, 30 patients had received the investigational treatment at doses ranging from 1.0 mg/kg to 12.0 mg/kg, administered once every three weeks.

Among 10 efficacy-evaluable patients with activating FGFR3 alterations treated at doses of 3.3 mg/kg or higher, nine demonstrated a reduction in tumour size.

Six patients achieved a partial response, representing a 60% response rate within this small efficacy-evaluable subgroup.

The findings provide preliminary evidence of antitumour activity in patients whose cancers carry the targeted genetic alterations.

However, the results are based on a limited number of patients in an early-stage clinical trial, and additional research will be necessary to establish the treatment’s efficacy and safety in larger populations.

Dose escalation remains ongoing as investigators continue evaluating the drug.

Responses Observed in Urothelial and Head and Neck Cancers

Biohaven reported responses across multiple cancer types associated with activating FGFR3 alterations.

Among five patients with urothelial cancer, three achieved a partial response following treatment with BHV-1530.

Responses were also observed in all three patients with human papillomavirus-positive (HPV-positive) head and neck squamous cell carcinoma included in the reported subgroup.

These findings suggest potential activity across different tumour types carrying relevant FGFR3 alterations, although the small patient numbers limit the conclusions that can be drawn.

The company also reported that all responding patients remained on treatment at the October 19 data cutoff.

Some patients had continued receiving BHV-1530 for more than six months.

The ongoing treatment of responding patients provides preliminary information about response durability, although the company has not established a definitive duration of benefit.

BHV-1530 Demonstrates Activity in Previously Treated Urothelial Cancer

The results included patients with urothelial cancer who had previously received established treatments for advanced disease.

According to Biohaven, all patients with urothelial cancer in the reported group had experienced disease progression following treatment with enfortumab vedotin combined with pembrolizumab.

The combination is a current first-line standard of care for advanced urothelial cancer.

Among the patients who responded to BHV-1530 was an individual who had also previously received an FGFR tyrosine kinase inhibitor.

The findings are relevant because they demonstrate preliminary activity in patients whose cancers had progressed despite earlier treatment.

However, the study remains in Phase 1 development, and the reported responses do not establish how BHV-1530 compares with existing therapies.

Further clinical evaluation will be required to determine whether the treatment can provide meaningful benefits in this patient population.

No Dose-Limiting Toxicities Reported Among 30 Patients

Biohaven also presented preliminary safety findings from the Phase 1 study.

Across all 30 patients who had received BHV-1530 as of the data cutoff, investigators reported no dose-limiting toxicities.

There were also no treatment-related serious adverse events or treatment-related deaths.

The most frequently reported adverse events were nausea and fatigue.

Nausea occurred in 43% of patients, while fatigue was reported in 37%.

Both adverse events were classified as Grade 1 or Grade 2, indicating mild to moderate severity.

The company also reported no cases of hyperphosphatemia, nail dystrophy, central serous retinopathy or interstitial lung disease.

These findings provide an initial indication of the drug’s tolerability during dose escalation.

Nevertheless, the safety profile remains preliminary, and additional patients and longer follow-up periods will be necessary to identify less common or delayed adverse effects.

Biohaven Plans Pivotal FGFR3 Cancer Study in First Half of 2027

Following the early clinical findings, Biohaven outlined plans to advance BHV-1530 into a pivotal study involving patients with FGFR3-altered tumours.

The company said it completed a Type C meeting with the US Food and Drug Administration (FDA) during the fourth quarter of 2026.

Biohaven intends to begin the proposed pivotal programme with patients who have urothelial cancer.

The study could start as early as the first half of 2027, subject to the company’s development preparations and regulatory considerations.

The programme is intended to generate clinical evidence that could potentially support an accelerated approval application.

However, accelerated approval is not guaranteed, and any future regulatory decision will depend on the results of further clinical studies and the FDA’s assessment of the submitted evidence.

The company has not disclosed a definitive timetable for a potential marketing application or regulatory decision.

Clinical Findings Presented at International Cancer Research Symposium

The Phase 1 findings were presented by Gerald S. Falchook, M.D., director of Sarah Cannon Research Institute at HCA HealthONE.

The presentation took place during an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

The symposium provides a forum for presenting research involving experimental cancer treatments, molecular targets and emerging therapeutic approaches.

Biohaven’s presentation focused on the preliminary efficacy and safety of BHV-1530, including its activity in patients with activating FGFR3 alterations.

The findings were reported in the company’s November 19, 2026 announcement and reflect data collected through October 19.

Additional trial results will be needed to determine whether the initial responses can be reproduced in larger patient groups.

BHV-1530 Development Outlook Supported by Early Clinical Activity

Biohaven’s Phase 1 results provided preliminary evidence of antitumour activity for BHV-1530 in patients with cancers carrying activating FGFR3 alterations.

Among the 10 efficacy-evaluable patients receiving doses of at least 3.3 mg/kg, nine experienced tumour reduction and six achieved partial responses.

The company also reported responses in urothelial cancer and HPV-positive head and neck squamous cell carcinoma, including patients who had previously received treatment for advanced disease.

The absence of dose-limiting toxicities and treatment-related serious adverse events among the 30 treated patients was another notable feature of the early findings.

However, the limited patient population, ongoing dose escalation and preliminary nature of the data mean that further clinical evaluation remains essential.

Biohaven’s proposed pivotal study, potentially beginning in the first half of 2027, represents the next planned development milestone for BHV-1530.

Investors will be monitoring additional efficacy and safety data, the design of the pivotal trial and regulatory developments as the company seeks to advance the investigational treatment towards a potential accelerated approval pathway.

Biohaven stock price

Mentioned In This Article

Latest News

Nov-19
Nov-19
Nov-05
Oct-29
Oct-26
Oct-22
Oct-22
Oct-22
Oct-22
Oct-09
Oct-09
Oct-08
Oct-02
Sep-28
Sep-11